Aerovate Therapeutics Inc... (AVTE)
Aerovate Therapeutics Statistics
Share Statistics
Aerovate Therapeutics has 28.98M shares outstanding. The number of shares has increased by 0.56% in one year.
| Shares Outstanding | 28.98M |
| Shares Change (YoY) | 0.56% |
| Shares Change (QoQ) | 0.38% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 21.13M |
| Failed to Deliver (FTD) Shares | 3.39K |
| FTD / Avg. Volume | 2.42% |
Short Selling Information
The latest short interest is 3.76M, so 13.02% of the outstanding shares have been sold short.
| Short Interest | 3.76M |
| Short % of Shares Out | 13.02% |
| Short % of Float | 19.19% |
| Short Ratio (days to cover) | 14.93 |
Valuation Ratios
The PE ratio is -1.09 and the forward PE ratio is -5.29. Aerovate Therapeutics's PEG ratio is 0.07.
| PE Ratio | -1.09 |
| Forward PE | -5.29 |
| PS Ratio | 0 |
| Forward PS | 3.2 |
| PB Ratio | 0.99 |
| P/FCF Ratio | -1.06 |
| PEG Ratio | 0.07 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Aerovate Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 20.93, with a Debt / Equity ratio of 0.01.
| Current Ratio | 20.93 |
| Quick Ratio | 20.93 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | -0.01 |
| Debt / FCF | -0.01 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-2.32M |
| Employee Count | 30 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 55K |
| Effective Tax Rate | -0.08% |
Stock Price Statistics
The stock price has increased by -91.38% in the last 52 weeks. The beta is 1, so Aerovate Therapeutics's price volatility has been higher than the market average.
| Beta | 1 |
| 52-Week Price Change | -91.38% |
| 50-Day Moving Average | 2.49 |
| 200-Day Moving Average | 2.35 |
| Relative Strength Index (RSI) | 53.57 |
| Average Volume (20 Days) | 140.38K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -74.6M |
| Net Income | -69.63M |
| EBITDA | -74.31M |
| EBIT | -74.6M |
| Earnings Per Share (EPS) | -2.44 |
Balance Sheet
The company has 33.75M in cash and 417K in debt, giving a net cash position of 33.33M.
| Cash & Cash Equivalents | 33.75M |
| Total Debt | 417K |
| Net Cash | 33.33M |
| Retained Earnings | -233.05M |
| Total Assets | 80.33M |
| Working Capital | 76.29M |
Cash Flow
In the last 12 months, operating cash flow was -71.2M and capital expenditures 0, giving a free cash flow of -71.2M.
| Operating Cash Flow | -71.2M |
| Capital Expenditures | 0 |
| Free Cash Flow | -71.2M |
| FCF Per Share | -2.49 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
AVTE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for AVTE is $2, which is -20.3% lower than the current price. The consensus rating is "Hold".
| Price Target | $2 |
| Price Target Difference | -20.3% |
| Analyst Consensus | Hold |
| Analyst Count | 7 |
Scores
| Altman Z-Score | 5.21 |
| Piotroski F-Score | 1 |